4PME
Human transthyretin (TTR) complexed with ferulic acid and curcumin.
4PME の概要
| エントリーDOI | 10.2210/pdb4pme/pdb |
| 関連するPDBエントリー | 4PM1 4PMF |
| 分子名称 | Transthyretin, (1Z,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,4,6-trien-3-one, SODIUM ION, ... (6 entities in total) |
| 機能のキーワード | human transthyretin (ttr) complexes, solubilization of hydrophobic ligands, curcumin degradation, thyroid hormone-binding protein |
| 由来する生物種 | Homo sapiens (Human) |
| 細胞内の位置 | Secreted: P02766 |
| タンパク質・核酸の鎖数 | 2 |
| 化学式量合計 | 26764.96 |
| 構造登録者 | |
| 主引用文献 | Ciccone, L.,Tepshi, L.,Nencetti, S.,Stura, E.A. Transthyretin complexes with curcumin and bromo-estradiol: evaluation of solubilizing multicomponent mixtures. N Biotechnol, 32:54-64, 2014 Cited by PubMed Abstract: Crystallographic structure determination of protein-ligand complexes of transthyretin (TTR) has been hindered by the low affinity of many compounds that bind to the central cavity of the tetramer. Because crystallization trials are carried out at protein and ligand concentration that approach the millimolar range, low affinity is less of a problem than the poor solubility of many compounds that have been shown to inhibit amyloid fibril formation. To achieve complete occupancy in co-crystallization experiments, the minimal requirement is one ligand for each of the two sites within the TTR tetramer. Here we present a new strategy for the co-crystallization of TTR using high molecular weight polyethylene glycol instead of high ionic strength precipitants, with ligands solubilized in multicomponent mixtures of compounds. This strategy is applied to the crystallization of TTR complexes with curcumin and 16α-bromo-estradiol. Here we report the crystal structures with these compounds and with the ferulic acid that results from curcumin degradation. PubMed: 25224922DOI: 10.1016/j.nbt.2014.09.002 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (1.264 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






